TradingView
RocketTickers
28 wrz 2018 16:33
U.S. FDA Approves VIZIMPRO® (dacomitinib)
Long
NYSE:PFE
Pfizer, Inc.
NYSE
Opis
⋅
28 wrz 2018 16:33
PFE: Pfizer Inc.
2018-09-27 17:41:00
U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
Beyond Technical Analysis
Komentarze
ForExtraPips
⋅
30 wrz 2018 18:40
Good to hear. I bought a call @ 43.00 on the 17th of Sep. Targeting between 52.00 and 55.00 by the end of this year.
Więcej